Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Whole-genome characterization of chemoresistant ovarian cancer|
Australian Ovarian Cancer Study Group
|Citation:||Nature, 2015; 521(7553):489-494|
|Ann-Marie Patch ... Karin S Kassahn ... The Australian Ovarian Cancer Study Group ... et al.|
|Abstract:||Patients with high-grade serous ovarian cancer (HGSC) have experienced little improvement in overall survival, and standard treatment has not advanced beyond platinum-based combination chemotherapy, during the past 30 years. To understand the drivers of clinical phenotypes better, here we use whole-genome sequencing of tumour and germline DNA samples from 92 patients with primary refractory, resistant, sensitive and matched acquired resistant disease. We show that gene breakage commonly inactivates the tumour suppressors RB1, NF1, RAD51B and PTEN in HGSC, and contributes to acquired chemotherapy resistance. CCNE1 amplification was common in primary resistant and refractory disease. We observed several molecular events associated with acquired resistance, including multiple independent reversions of germline BRCA1 or BRCA2 mutations in individual patients, loss of BRCA1 promoter methylation, an alteration in molecular subtype, and recurrent promoter fusion associated with overexpression of the drug efflux pump MDR1.|
|Keywords:||Cancer genomics; Ovarian cancer|
|Description:||Martin K Oehler is a member of the Australian Ovarian Cancer Study Group|
|Rights:||© 2015 Macmillian Publishers Ltd.|
|Appears in Collections:||Paediatrics publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.